Aprea Therapeutics Inc

NASDAQ:APRE   3:59:53 PM EDT
4.36
+0.02 (+0.46%)
Products, Regulatory, Earnings Announcements

Aprea Therapeutics Announces Positive Results From Trial Of Eprenetapopt + Azacitidine

Published: 07/21/2021 12:52 GMT
Aprea Therapeutics Inc (APRE) - Aprea Therapeutics Announces Positive Results From Phase 2 Trial of Eprenetapopt + Azacitidine for Post-transplant Maintenance Therapy in Tp53 Mutant Mds and Aml.
Aprea Therapeutics Inc - 58% Relapse Free Survival at 1 Year Post-transplant.
Aprea Therapeutics Inc - 79% Overall Survival at 1 Year Post-transplant.
Aprea Therapeutics Inc - Post- Transplant Regimen of Eprenetapopt and Azacitidine Was Well Tolerated Among Patients in Clinical Trial.
Aprea Therapeutics Inc - Plans to Discuss Data From Phase 2 Clinical Trial With U.S. FDA in Second Half of 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.48

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.47

More details on our Analysts Page.